Jounce Therapeutics (United States)

Alternate names: Jounce Therapeutics, Jounce Therapeutics, Inc.

ROR: 03grjwb46

OpenAlex ID: I4405272070

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

2020 · Robert J. Motzer, Paul B. Robbins, et al. · Nature Medicine · 528

The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

2020 · Janis M Taube, Guray Akturk, et al. · Journal for ImmunoTherapy of Cancer · 299

PDF

In vivo discovery of immunotherapy targets in the tumour microenvironment

2014 · Penghui Zhou, Donald R. Shaffer, et al. · Nature · 238

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

2022 · Edward Seung, Zhen Xing, et al. · Nature · 172

Five birds, one stone: Neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody

2014 · Harald Rouha, Adriana Badarau, et al. · mAbs · 147

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

2014 · Heather A Huet, Joseph D Growney, et al. · mAbs · 115

PDF

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance

2014 · Akinori Yoda, Guillaume Adelmant, et al. · Nature Medicine · 109

TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice

2015 · Jing Wen, Jessica Doerner, et al. · Journal of Autoimmunity · 106

Deficiency of Fibroblast Growth Factor-Inducible 14 (Fn14) Preserves the Filtration Barrier and Ameliorates Lupus Nephritis

2014 · Yumin Xia, Leal C. Herlitz, et al. · Journal of the American Society of Nephrology · 89

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

2022 · Timothy A. Yap, Justin F. Gainor, et al. · Clinical Cancer Research · 84

PDF

Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors

2017 · Amy Bregar, Amit Deshpande, et al. · Gynecologic Oncology · 70

PDF

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

2022 · Jessica D. Weaver, Edward C. Stack, et al. · OncoImmunology · 61

TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus

2015 · Jessica L. Doerner, Jing Wen, et al. · Journal of Investigative Dermatology · 57

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine

2017 · Masafumi Ikeda, Tatsuya Ioka, et al. · Cancer Science · 46

PDF

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

2022 · Kara W. Chew, Carlee Moser, et al. · Nature Communications · 44

PDF

Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells

2019 · Kankana Bardhan, Halil-Ibrahim Aksoylar, et al. · Scientific Reports · 44

PDF

Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors

2023 · Ben Umiker, Yasmin Hashambhoy-Ramsay, et al. · Molecular Cancer Therapeutics · 41

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

2020 · Amanda Hanson, Kutlu Elpek, et al. · PLoS ONE · 40

PDF

Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium

2023 · Heather M. Callaway, Kathryn M. Hastie, et al. · Cell Reports · 39

PDF

Toll-like receptor 9 negatively regulates pancreatic islet beta cell growth and function in a mouse model of type 1 diabetes

2018 · Mengju Liu, Jian Peng, et al. · Diabetologia · 37

PDF

Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.

2017 · Howard A. Burris, Margaret K. Callahan, et al. · Journal of Clinical Oncology · 34

ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.

2018 · Timothy Anthony Yap, Howard A. Burris, et al. · Journal of Clinical Oncology · 31

Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial

2022 · Honghu Liu, Yan Wang, et al. · EBioMedicine · 25

ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control

2022 · Tiffany Blair, Jason Baird, et al. · Scientific Reports · 20

PDF

A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells

2022 · Walter Hanel, Pushpa Lata, et al. · Experimental Hematology and Oncology · 14

PDF

Works count: 81

Citation count: 10,080